Opinion

Video

Utilization of 68Gallium PSMA-11 in Clinical Practice

Author(s):

Oliver Sartor, MD

Key Takeaways

  • 68gallium PSMA-11 gozetotide is essential for prostate cancer imaging but faces production and distribution challenges.
  • Expanding production facilities and streamlining regulatory processes could enhance availability.
SHOW MORE

The panelist discusses how the limited availability of 68gallium PSMA-11 gozetotide in clinical practice poses challenges and suggests potential strategies to increase accessibility, such as expanding production facilities, improving distribution networks, and exploring alternative radiotracers with longer half-lives.

Discuss the availability of use 68gallium PSMA-11 gozetotide in clinical practice. What are potential strategies to increase availability?

Related Videos
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor
Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | © Dr_Microbe - stock.adobe.com
February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor
"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor
"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | © Dr_Microbe - stock.adobe.com
February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor
In both racial cohorts, median MFS was not reached in the darolutamide group.
© 2025 MJH Life Sciences

All rights reserved.